Files
Abstract
Obesity alters pharmacokinetics (PK) of contraceptive hormones and has the potential to contribute to contraceptive failure. It is also a risk factor for venous thromboembolism (VTE). The current project aims to study the influence of the binding protein sex hormone binding globulin (SHBG) on levonorgestrel (LNG) pharmacokinetics, and to study changes in anticoagulation parameters protein C activity and free protein S, in a population of obese women initiating combined oral contraceptive pills (COCs).